Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study

Goh, Louise Gek Huang; Sun, Jie; Ong, Benjamin Shao Kiat; Khoo, D. H. C.; Sum, Chee Fang; Ng, Kwong

doi:10.1007/s40200-022-01004-4

Cited by 4 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genetik, kültürel ve çevresel değişkenlerin, ilaç yanıtlarında farklılıklara neden olabileceği bilinmektedir (35). Son yıllarda DPP4-i'lerini ve SGLT2i'lerini de bu açıdan ele alan çalışmalar da artmaktadır (36,37). Türkiye' de, yüksek akraba evliliklerinin gen havuzuna etkisi düşünüldüğünde ilaç etkilerini değerlendirmenin ayrı bir öneme sahip olabileceği düşünülebilir.…”

Section: Discussionunclassified

Sodyum Glukoz Ko-Transporter 2 İnhibitörü ve Dipeptidil Peptidaz-4 İnhibitörü İlaçların Kan Üre Düzeyi Üzerine Etkiler

Çelik

2023

Mevmedsci

View full text Add to dashboard Cite

Effects of Sodium Glucose Co-transporter 2 Inhibitors and DipeptidylPeptidase-4 Inhibitors on Blood Urea Level ÖZET Amaç: Glukagon, salınımının sodyum-glukoz ko-transporter 2 inhibitörü(SGLT2i) kullanımı ile arttığı, dipeptidil peptidaz-4 inhibitörü(DPP-4i) kullanımı ile azaldığı bilinmektedir. Glukagon üzerine farklı yönde etkileri göz önüne alınarak bu çalışmada, bu iki grup ilacı kullanan hastaların kan üre düzeylerini ve tahmini glomerüler filtrasyon hızını(eGFR) birlikte ele alarak değerlendirmek amaçlanmıştır. Yöntem: SGLT2i grubunda 109 ve DPP4igrubunda 111 olmak üzere 220 hasta çalışmaya dâhil edilmiştir.Hastaların tedaviye başlamadan önce, tedaviden 1-3 ay sonra ve tedaviden 4-6 ay sonra yapılan kan testleri retrospektif olarak değerlendirilmiştir. Bulgular: SGLT2i grubunda kan üre düzeyinde, kreatinin ve eGFR 0., 1. ve 2. viziteler arasında istatistiksel olarak anlamlı fark saptanmıştır. DPP-4i grubunda ise kan üre düzeyinde ve eGFR 0., 1. ve 2. viziteler arasında istatistiksel olarak anlamlı farklılık saptanmamıştır. Sonuç: Kan üre düzeyinin SGLT2i kullanan hastalarda artarken, DPP-4i kullanan hastalarda değişmediği saptanmıştır. Bu ilaçları hem monoterapi hem de kombine tedavi olarak değerlendirmeye alan, aynı zamanda bu ilacı kullananlarda plazma glukagon seviyelerinin üre ile etkileşimini değerlendiren prospektif çalışmalara ihtiyaç vardır.Anahtar Kelimeler: Dipeptidil peptidaz-4 inhibitörü, kan üre nitrojeni, sodyum glukoz ko-transporter 2 inhibitörü, tahmini glomerüler filtrasyon hızı, diyabetik nefropati, tip 2 diyabet ABSTRACT Aim: Glucagon is known that its secretion increases with the use of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and decreases with the use of dipeptidyl peptidase-4 inhibitor (DPP-4i). Considering the different effects on glucagon, in this study, it was aimed to evaluate the blood urea levels and estimated glomerular filtration rate in patients using these two groups of drugs together. Methods: 220 patients, 109 in the SGLT2i group and 111 in the DPP4i group, were included in the study.Patients before the start of treatment, after treatment 1-3. month and 4-6. month after treatment blood tests were evaluated retrospectively.Results: In the SGLT2i group, there was a statistically significant difference in blood urea level, creatinine and estimated glomerular filtration rate between visits 0, 1 and 2. In the DPP-4i group, there was no statistically significant difference in blood urea level and estimated glomerular filtration rate between visits 0, 1 and 2. Conclusion: It was found that blood urea level increased in patients using SGLT2i, while it did not change in patients using DPP-4i. There is a need for prospective studies that evaluate these drugs as both monotherapy and combination therapy, and also evaluate the interaction of plasma glucagon levels with urea in those using this drug.

show abstract

Section: Discussionunclassified

Sodyum Glukoz Ko-Transporter 2 İnhibitörü ve Dipeptidil Peptidaz-4 İnhibitörü İlaçların Kan Üre Düzeyi Üzerine Etkiler

Çelik

2023

Mevmedsci

View full text Add to dashboard Cite

show abstract

“…Jednakże leki te wykazują różnice w sile działania pomiędzy poszczególnymi grupami etnicznymi. Kanagliflozyna jest bardziej skuteczna u osób rasy czarnej i kaukaskiej, w porównaniu do osób żółtej natomiast empagliflozyna jest skuteczniejsza u osób rasy żółtej i kaukaskiej w porównaniu z osobami rasy czarnej [20,21].…”

Section: Ive Leki Z Grupy Inhibitorów Sglt2unclassified

Gliflozins and their beneficial hypoglycaemic effect profile and prevention of cardiovascular complications in patients treated for type II diabetes mellitus

Natalia

Rafał²,

Banasiak³

et al. 2023

View full text Add to dashboard Cite

Introduction: Diabetes mellitus type 2 (DM2) is a population disease, it is predicted that by 2030 the DM2 will affect 7% of the population. Patients due to progress of the disease in case of micro and macro angiovascular changes develop organ complications mainly in terms of cardiovascular disease (CV). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are relatively new group of drugs that apart from the hypoglycemic effect, also have other beneficial effects. Due to the scale and importance of the problem of diabetes complications researchers from around the world are working on its solution. Aim of the study: The aim of this study was to present the effects of SGLT2 inhibitors on cardiovascular complications in DM2 patients. Methods and materials We reviewed the literature contained in the PubMed database, using keywords: „Diabetes type 2”; „SGLT2 inhibitors”; „Cardiovascular disease”; „Heart failure” Results: In addition to their hypoglycaemic effects, SGLT2 inhibitors have also been shown to have beneficial effects on the CV system. Studies have shown that in DM2 patients treated with gliflozins, the risk of hospitalisation for heart failure decreased by 35% and the risk of death from cardiovascular causes by 38%. Retrospective studies have been carried out in which the efficacy of all drugs in the group in question, and not just individual substances, has been proven. In clinical experiments, phlazines were confirmed to reduce the risk of CV complications, including heart failure, myocardial infarction, angina, stroke or atrial fibrillation. Conclusions: SGLT2 drugs reduce the risk of cardiovascular complications and reduce hospitalisations for heart failure in patients with DM2. Future studies should seek to determine at what stage treatment should be implemented to maximise the resulting benefits to the patient.

show abstract

Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study

Pallarés-Carratalá,

Ruiz-García,

Serrano-Cumplido

et al. 2024

Clínica e Investigación en Arteriosclerosis

View full text Add to dashboard Cite

Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study

Cited by 4 publications

References 59 publications

Sodyum Glukoz Ko-Transporter 2 İnhibitörü ve Dipeptidil Peptidaz-4 İnhibitörü İlaçların Kan Üre Düzeyi Üzerine Etkiler

Sodyum Glukoz Ko-Transporter 2 İnhibitörü ve Dipeptidil Peptidaz-4 İnhibitörü İlaçların Kan Üre Düzeyi Üzerine Etkiler

Gliflozins and their beneficial hypoglycaemic effect profile and prevention of cardiovascular complications in patients treated for type II diabetes mellitus

Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study

Contact Info

Product

Resources

About